HC Wainwright Reaffirms “Neutral” Rating for AnaptysBio (NASDAQ:ANAB)

HC Wainwright reiterated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $22.00 price target on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. Wolfe Research started coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target on the stock. Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Wells Fargo & Company increased their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.11.

AnaptysBio Stock Down 2.1 %

Shares of AnaptysBio stock opened at $16.40 on Tuesday. The business has a fifty day simple moving average of $16.16 and a 200 day simple moving average of $24.22. The stock has a market cap of $499.04 million and a PE ratio of -2.70. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Analysts expect that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was acquired at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

A number of large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in shares of AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in AnaptysBio in the 4th quarter valued at about $40,000. AlphaQuest LLC grew its holdings in AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares during the period. Virtus ETF Advisers LLC increased its position in AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 5,360 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.